Abstract: The invention relates to novel pharmaceutical dosage forms of varenicline, which are useful for aiding smoking cessation and which have good storage stability. In particular, the present invention relates to formulations of varenicline wherein the dosage forms that are produced therefrom generate under specified storage conditions less than about 4% on a weight basis of the N-formyl and N-methyl degradation products.
Abstract: The present invention provides methods of treating cancer of the liver, ovarian cancer, a desmoid tumor, glioma, pancreatic cancer, or renal cell carcinoma using an estrogen agonist/antagonist. The present invention also provides kits that contain an estrogen agonist/antagonist for treating cancer of the liver, ovarian cancer, a desmoid tumor, glioma, pancreatic cancer, or renal cell carcinoma.
Abstract: Chemokine receptor antagonists, in particular, bicyclic diamine compounds of Formula (I) that act as antagonists of chemokine CCR2 and CCR3 receptors including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation are described herein.
Type:
Grant
Filed:
March 6, 2002
Date of Patent:
November 23, 2004
Assignee:
Pfizer Inc
Inventors:
Roberto Colon-Cruz, Mary T. Didiuk, Erin M. Duffy, Ravi Garigipati, Wan F. Lau, Wayne S. McDonald
Abstract: This invention relates to methods of treating traumatic brain injury (TBI) or hypoxic or ischemic stroke, comprising administering to a patient in need of such treatment an NR2B subtype selective N-methyl-D-aspartate (NMDA) receptor antagonist in combination with either: (a) a sodium channel antagonist; (b) a nitric oxide synthase (NOS) inhibitor; (c) a glycine site antagonist; (d) a potassium channel opener; (e) an AMPA/kainate receptor antagonist; (f) a calcium channel antagonist; (g) a GABA-A receptor modulator (e.g., a GABA-A receptor agonist); or (h) an antiinflammatory agent. This invention also relates to methods of treating hypoxic or ischemic stroke comprising administering to a patient in need of such treatment an NMDA receptor antagonist in combination with a thrombolytic agent.
Type:
Grant
Filed:
September 6, 2001
Date of Patent:
November 23, 2004
Assignee:
Pfizer, Inc.
Inventors:
Bertrand L. Chenard, Frank S. Menniti, Mario D. Saltarelli
Abstract: Compounds of formula (I):
and their salts, solvates, hydrates and prodrugs are useful PCP inhibitors, processes for making the same, compositions comprising the same, and methods of treating a PCP-mediated condition or disease using the same.
Type:
Grant
Filed:
March 29, 2002
Date of Patent:
November 23, 2004
Assignee:
Pfizer Inc.
Inventors:
Simon Bailey, Paul Vincent Fish, Kim James, Gavin Alistar Whitlock
Abstract: A compound of the formula
whereon
R1 is:
R5 is:
and n, m, Z, R8, R9, R10 and R11 are as defined herein, useful in the treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly myocardial ischemia.
Abstract: A method and a device for the analysis of products in the form of a capsule, and of empty capsules, by means of NIR reflection spectroscopy are provided wherein the capsule is rotated around at least one axis during the recording of the reflection spectrum. Means for rotating the capsule are also provided.
Abstract: The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor.
Type:
Application
Filed:
November 10, 2003
Publication date:
November 18, 2004
Applicants:
NEUROGEN CORPORATION, PFIZER INC.
Inventors:
Raymond F. Horvath, Jennifer N. Tran, Stephane De Lombaert, Kevin J. Hodgetts, Philip A. Carpino, David A. Griffith
Abstract: The present invention relates to the use of a modulator of the Kiss-1 receptor for the treatment of blood pressure disorders, in particular to the use of a Kiss-1 receptor antagonist for the treatment of hypertension. The invention also provides methods of screening for compounds useful in the treatment of hypertension.
Abstract: The present invention relates to new pharmaceutical uses for compounds that exhibit activity as nitric oxide synthase (NOS) inhibitors. Specifically, it relates to the use of NOS inhibitors, particularly selective neuronal NOS (nNOS) inhibitors, alone or in combination with another active agent, in particular, either an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions the treatment which can be effected or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder; jet lag, circadian sleep rhythms disorder, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycle disorders, narcolepsy and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis, and restless-legs syndrome.
Type:
Application
Filed:
June 14, 2004
Publication date:
November 18, 2004
Applicant:
Pfizer Inc
Inventors:
Mario David Saltarelli, John Adams Lowe
Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
Type:
Application
Filed:
July 1, 2003
Publication date:
November 18, 2004
Applicants:
Pfizer Inc., Abgenix, Inc.
Inventors:
Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
Abstract: This invention describes a convenient method for the preparation and use of a ruthenium catalyst for a chiral reduction of ketones and imines.
Abstract: Pharmaceutical compositions are disclosed for the treatment of nicotine dependence or addiction, tobacco dependence or addiction, reduction of nicotine withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse or other behavioral dependencies. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and a CB-1 receptor antagonist and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.
Type:
Application
Filed:
March 4, 2004
Publication date:
November 11, 2004
Applicant:
Pfizer Inc
Inventors:
Jotham W. Coe, Philip A. Iredale, Steven B. Sands
Abstract: A novel use of an inhibitor of protein kinase C (PKC) for suppressing the sustained slow postsynaptic excitation (SSPE) caused by prolonged stimulation of synaptic inputs to intrinsic primary afferent neurons (IPANs), is provided. Since the generation of SSPE requires a phosphorylation step mediated by protein kinase C, PKC inhibitors, such as staurosporine, RO31-8220 or calphostin C is useful for a method for the treatment of a patient having a need to suppress the sustained slow postsynaptic excitation (SSPE) caused by prolonged stimulation of synaptic inputs to intrinsic primary afferent neurons (IPANs), such as intestinal hypersensitivity, irritable bowel syndrome (IBS), non-ulcer dyspepsia, or other conditions that may derive from long-term changes in the behavior of enteric neurons.
Abstract: The invention relates to nicotinamide derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The nicotinamide derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic, respiratory diseases, disorders and conditions, as well as wounds.
Type:
Application
Filed:
June 9, 2004
Publication date:
November 11, 2004
Applicant:
Pfizer Inc.
Inventors:
Simon Balley, Elisabeth C. L. Gautier, Alan J. Henderson, Thomas V. Magee, Anthony Marfat, John P. Mathias, Dale G. McLeod, Sandra M. Monaghan, Blanda L. C. Stammen